How will you select patients with brain metastases for TTFields?
The METIS study included only NSCLC patients and found a greater impact for patients previously treated with ICI. How does this impact your patient selection?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Plenary Session Presentation "Tumor Treating Fields (TTFields) After Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM): Final Results of The Phase 3 METIS Trial" by Dr. @Dr. First Last.
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · Florida International University
Answered on
The METIS trial restricted eligibility only to patients with brain metastases from non-small cell lung cancer. Therefore, we would not be able to extrapolate these results and data to other tumor types and histologies. Indeed, a post hoc analysis of the data did demonstrate a greater impact in patie...
Join for free or sign in to see the full answer
Mednet Member
Radiation Oncology · Clearview Cancer Institute
Answered on · Updated on
I congratulate the authors on a well-designed and conducted trial asking an important question. I currently offer TTF to my GBM patients, and some choose to use it.
I would like to see a cost-effectiveness analysis of TTF in this setting. Time to neurocognitive failure, OS, and radiological response...
Join for free or sign in to see the full answer